Anti‐androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation <i>via</i> altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals
Anti‐androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation <i>via</i> altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Anti‐androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation <i>via</i> altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals have?
Anti‐androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation <i>via</i> altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals has 57 citations in the OpenAlex counts ScholarIQ stores.
When was Anti‐androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation <i>via</i> altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals published?
Anti‐androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation <i>via</i> altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals has 2015 year in the ScholarIQ index.
What is the open-access status of Anti‐androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation <i>via</i> altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals?
Anti‐androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation <i>via</i> altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals has bronze oa status in the ScholarIQ index.
What is the DOI of Anti‐androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation <i>via</i> altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals?
The DOI for Anti‐androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation <i>via</i> altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals is on the source record.
What is the PMID of Anti‐androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation <i>via</i> altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals?
The PMID for Anti‐androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation <i>via</i> altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals is on the source record.
What is the OpenAlex record for Anti‐androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation <i>via</i> altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals?
The OpenAlex for Anti‐androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation <i>via</i> altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals is on the source record.